SI9300514A - Immunopotentiatory agent and physiologically acceptable salts thereof - Google Patents

Immunopotentiatory agent and physiologically acceptable salts thereof Download PDF

Info

Publication number: SI9300514A
Authority: SI; Slovenia
Prior art keywords: physiologically acceptable; compound; group; acceptable salt; hydrogen
Prior art date: 1992-10-01

Application number

SI9300514A

Other languages

English (en)

Slovenian (sl)

Inventor

John Richard Rhodes

Original Assignee

Wellcome Found

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-10-01

Filing date

1993-09-30

Publication date

1994-06-30

1992-10-01 Priority claimed from GB929220715A external-priority patent/GB9220715D0/en

1992-12-23 Priority claimed from GB929226874A external-priority patent/GB9226874D0/en

1993-09-30 Application filed by Wellcome Found filed Critical Wellcome Found

1994-06-30 Publication of SI9300514A publication Critical patent/SI9300514A/sl

Links

150000003839 salts Chemical class 0.000 title claims abstract description 60
150000001875 compounds Chemical class 0.000 claims abstract description 120
206010028980 Neoplasm Diseases 0.000 claims abstract description 37
208000015181 infectious disease Diseases 0.000 claims abstract description 25
238000011282 treatment Methods 0.000 claims abstract description 24
239000003814 drug Substances 0.000 claims abstract description 21
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 15
201000010099 disease Diseases 0.000 claims abstract description 14
238000011321 prophylaxis Methods 0.000 claims abstract description 14
238000004519 manufacturing process Methods 0.000 claims abstract description 11
XEDONBRPTABQFB-UHFFFAOYSA-N 4-[(2-formyl-3-hydroxyphenoxy)methyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1COC1=CC=CC(O)=C1C=O XEDONBRPTABQFB-UHFFFAOYSA-N 0.000 claims abstract description 8
230000000259 anti-tumor effect Effects 0.000 claims abstract description 4
210000001744 T-lymphocyte Anatomy 0.000 claims description 31
229910052739 hydrogen Inorganic materials 0.000 claims description 28
125000000217 alkyl group Chemical group 0.000 claims description 26
230000036039 immunity Effects 0.000 claims description 25
238000002360 preparation method Methods 0.000 claims description 25
239000001257 hydrogen Substances 0.000 claims description 24
201000011510 cancer Diseases 0.000 claims description 18
239000002262 Schiff base Substances 0.000 claims description 17
150000004753 Schiff bases Chemical class 0.000 claims description 16
230000028993 immune response Effects 0.000 claims description 16
-1 cyano, carboxyl Chemical group 0.000 claims description 15
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 14
150000002431 hydrogen Chemical group 0.000 claims description 12
125000004432 carbon atom Chemical group C* 0.000 claims description 11
230000002708 enhancing effect Effects 0.000 claims description 11
230000009385 viral infection Effects 0.000 claims description 11
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 10
208000036142 Viral infection Diseases 0.000 claims description 10
239000003623 enhancer Substances 0.000 claims description 10
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 10
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 10
229910052760 oxygen Inorganic materials 0.000 claims description 9
241000725303 Human immunodeficiency virus Species 0.000 claims description 8
125000003545 alkoxy group Chemical group 0.000 claims description 8
238000000034 method Methods 0.000 claims description 8
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 7
239000001301 oxygen Substances 0.000 claims description 7
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 6
125000003277 amino group Chemical group 0.000 claims description 6
125000002947 alkylene group Chemical group 0.000 claims description 5
229910052799 carbon Inorganic materials 0.000 claims description 5
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 4
125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 4
150000007857 hydrazones Chemical class 0.000 claims description 4
230000002685 pulmonary effect Effects 0.000 claims description 4
125000001424 substituent group Chemical group 0.000 claims description 4
ZFBRJUBOJXNIQM-UHFFFAOYSA-N Atropaldehyde Chemical compound O=CC(=C)C1=CC=CC=C1 ZFBRJUBOJXNIQM-UHFFFAOYSA-N 0.000 claims description 3
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 3
ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 3
CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 claims description 3
125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 2
XHLHPRDBBAGVEG-UHFFFAOYSA-N 1-tetralone Chemical group C1=CC=C2C(=O)CCCC2=C1 XHLHPRDBBAGVEG-UHFFFAOYSA-N 0.000 claims description 2
GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 claims description 2
ACZGCWSMSTYWDQ-UHFFFAOYSA-N 3h-1-benzofuran-2-one Chemical group C1=CC=C2OC(=O)CC2=C1 ACZGCWSMSTYWDQ-UHFFFAOYSA-N 0.000 claims description 2
206010009944 Colon cancer Diseases 0.000 claims description 2
208000005176 Hepatitis C Diseases 0.000 claims description 2
229930192627 Naphthoquinone Chemical group 0.000 claims description 2
125000005236 alkanoylamino group Chemical group 0.000 claims description 2
239000004599 antimicrobial Substances 0.000 claims description 2
125000004429 atom Chemical group 0.000 claims description 2
125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 2
125000001188 haloalkyl group Chemical group 0.000 claims description 2
229910052736 halogen Inorganic materials 0.000 claims description 2
150000002367 halogens Chemical class 0.000 claims description 2
208000002672 hepatitis B Diseases 0.000 claims description 2
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
125000000896 monocarboxylic acid group Chemical group 0.000 claims description 2
239000002246 antineoplastic agent Substances 0.000 claims 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
229960005475 antiinfective agent Drugs 0.000 claims 1
150000001721 carbon Chemical group 0.000 claims 1
229940127089 cytotoxic agent Drugs 0.000 claims 1
239000002955 immunomodulating agent Substances 0.000 claims 1
FRASJONUBLZVQX-UHFFFAOYSA-N naphthoquinone group Chemical group C1(C=CC(C2=CC=CC=C12)=O)=O FRASJONUBLZVQX-UHFFFAOYSA-N 0.000 claims 1
239000000203 mixture Substances 0.000 abstract description 13
239000003795 chemical substances by application Substances 0.000 abstract description 9
229940079593 drug Drugs 0.000 abstract description 7
230000002924 anti-infective effect Effects 0.000 abstract description 2
239000000427 antigen Substances 0.000 description 37
108091007433 antigens Proteins 0.000 description 37
102000036639 antigens Human genes 0.000 description 37
210000004027 cell Anatomy 0.000 description 26
241000699670 Mus sp. Species 0.000 description 23
241000700605 Viruses Species 0.000 description 17
210000000987 immune system Anatomy 0.000 description 15
IPRPPFIAVHPVJH-UHFFFAOYSA-N (4-hydroxyphenyl)acetaldehyde Chemical compound OC1=CC=C(CC=O)C=C1 IPRPPFIAVHPVJH-UHFFFAOYSA-N 0.000 description 14
239000000243 solution Substances 0.000 description 14
206010061598 Immunodeficiency Diseases 0.000 description 13
238000012360 testing method Methods 0.000 description 13
239000004480 active ingredient Substances 0.000 description 12
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
230000000694 effects Effects 0.000 description 11
238000002347 injection Methods 0.000 description 11
239000007924 injection Substances 0.000 description 11
239000007788 liquid Substances 0.000 description 10
208000030507 AIDS Diseases 0.000 description 9
208000029462 Immunodeficiency disease Diseases 0.000 description 9
239000002253 acid Substances 0.000 description 9
230000007813 immunodeficiency Effects 0.000 description 9
230000015572 biosynthetic process Effects 0.000 description 8
230000036737 immune function Effects 0.000 description 8
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
239000000843 powder Substances 0.000 description 8
239000008215 water for injection Substances 0.000 description 8
241000282412 Homo Species 0.000 description 7
230000002950 deficient Effects 0.000 description 7
239000003826 tablet Substances 0.000 description 7
BUQFPKIVQGBELU-UHFFFAOYSA-N 2,3-dioxoheptanoic acid Chemical compound CCCCC(=O)C(=O)C(O)=O BUQFPKIVQGBELU-UHFFFAOYSA-N 0.000 description 6
108020004414 DNA Proteins 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
108091008874 T cell receptors Proteins 0.000 description 6
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 6
239000002671 adjuvant Substances 0.000 description 6
230000037396 body weight Effects 0.000 description 6
230000000139 costimulatory effect Effects 0.000 description 6
239000008187 granular material Substances 0.000 description 6
239000004615 ingredient Substances 0.000 description 6
210000001165 lymph node Anatomy 0.000 description 6
239000002245 particle Substances 0.000 description 6
239000000725 suspension Substances 0.000 description 6
230000001225 therapeutic effect Effects 0.000 description 6
241001529453 unidentified herpesvirus Species 0.000 description 6
241000701085 Human alphaherpesvirus 3 Species 0.000 description 5
108010047620 Phytohemagglutinins Proteins 0.000 description 5
239000000969 carrier Substances 0.000 description 5
230000004940 costimulation Effects 0.000 description 5
230000001506 immunosuppresive effect Effects 0.000 description 5
238000000338 in vitro Methods 0.000 description 5
230000001965 increasing effect Effects 0.000 description 5
230000000977 initiatory effect Effects 0.000 description 5
210000004698 lymphocyte Anatomy 0.000 description 5
230000007246 mechanism Effects 0.000 description 5
230000001885 phytohemagglutinin Effects 0.000 description 5
230000009993 protective function Effects 0.000 description 5
230000004044 response Effects 0.000 description 5
238000002054 transplantation Methods 0.000 description 5
CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
241000701044 Human gammaherpesvirus 4 Species 0.000 description 4
206010062016 Immunosuppression Diseases 0.000 description 4
241000124008 Mammalia Species 0.000 description 4
241000699666 Mus <mouse, genus> Species 0.000 description 4
206010035664 Pneumonia Diseases 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
239000002775 capsule Substances 0.000 description 4
125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
230000001684 chronic effect Effects 0.000 description 4
230000007547 defect Effects 0.000 description 4
230000007812 deficiency Effects 0.000 description 4
239000011521 glass Substances 0.000 description 4
230000003993 interaction Effects 0.000 description 4
239000003446 ligand Substances 0.000 description 4
235000019359 magnesium stearate Nutrition 0.000 description 4
230000001404 mediated effect Effects 0.000 description 4
230000002085 persistent effect Effects 0.000 description 4
239000001267 polyvinylpyrrolidone Substances 0.000 description 4
229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
239000003380 propellant Substances 0.000 description 4
239000000126 substance Substances 0.000 description 4
229940124597 therapeutic agent Drugs 0.000 description 4
229950009795 tucaresol Drugs 0.000 description 4
206010011831 Cytomegalovirus infection Diseases 0.000 description 3
208000031886 HIV Infections Diseases 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
241000233870 Pneumocystis Species 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
150000001408 amides Chemical class 0.000 description 3
HAMNKKUPIHEESI-UHFFFAOYSA-N aminoguanidine Chemical compound NNC(N)=N HAMNKKUPIHEESI-UHFFFAOYSA-N 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
238000009833 condensation Methods 0.000 description 3
230000005494 condensation Effects 0.000 description 3
238000011161 development Methods 0.000 description 3
230000018109 developmental process Effects 0.000 description 3
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
208000006454 hepatitis Diseases 0.000 description 3
231100000283 hepatitis Toxicity 0.000 description 3
239000003018 immunosuppressive agent Substances 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
239000003112 inhibitor Substances 0.000 description 3
238000007918 intramuscular administration Methods 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
239000008101 lactose Substances 0.000 description 3
230000003211 malignant effect Effects 0.000 description 3
210000000214 mouth Anatomy 0.000 description 3
229940100662 nasal drops Drugs 0.000 description 3
244000052769 pathogen Species 0.000 description 3
230000001717 pathogenic effect Effects 0.000 description 3
201000000317 pneumocystosis Diseases 0.000 description 3
230000000306 recurrent effect Effects 0.000 description 3
230000004043 responsiveness Effects 0.000 description 3
238000010561 standard procedure Methods 0.000 description 3
230000000638 stimulation Effects 0.000 description 3
238000003756 stirring Methods 0.000 description 3
239000000829 suppository Substances 0.000 description 3
229960000814 tetanus toxoid Drugs 0.000 description 3
229960005486 vaccine Drugs 0.000 description 3
230000003612 virological effect Effects 0.000 description 3
XSSYCIGJYCVRRK-RQJHMYQMSA-N (-)-carbovir Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1C[C@H](CO)C=C1 XSSYCIGJYCVRRK-RQJHMYQMSA-N 0.000 description 2
LTMWBQRMYYUNSH-UHFFFAOYSA-N 3-hydroxy-1-(4-methoxyphenyl)-3-methylbutan-2-one Chemical compound COC1=CC=C(CC(=O)C(C)(C)O)C=C1 LTMWBQRMYYUNSH-UHFFFAOYSA-N 0.000 description 2
WYEPBHZLDUPIOD-UHFFFAOYSA-N 4,6-dioxoheptanoic acid Chemical compound CC(=O)CC(=O)CCC(O)=O WYEPBHZLDUPIOD-UHFFFAOYSA-N 0.000 description 2
206010001513 AIDS related complex Diseases 0.000 description 2
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
206010006187 Breast cancer Diseases 0.000 description 2
208000026310 Breast neoplasm Diseases 0.000 description 2
241000701022 Cytomegalovirus Species 0.000 description 2
238000002965 ELISA Methods 0.000 description 2
208000010201 Exanthema Diseases 0.000 description 2
241001290006 Fissurella Species 0.000 description 2
208000037357 HIV infectious disease Diseases 0.000 description 2
206010019233 Headaches Diseases 0.000 description 2
206010019799 Hepatitis viral Diseases 0.000 description 2
208000009889 Herpes Simplex Diseases 0.000 description 2
208000007514 Herpes zoster Diseases 0.000 description 2
OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
102000006992 Interferon-alpha Human genes 0.000 description 2
108010047761 Interferon-alpha Proteins 0.000 description 2
102000014150 Interferons Human genes 0.000 description 2
108010050904 Interferons Proteins 0.000 description 2
108010058846 Ovalbumin Proteins 0.000 description 2
206010033799 Paralysis Diseases 0.000 description 2
229920001213 Polysorbate 20 Polymers 0.000 description 2
206010037660 Pyrexia Diseases 0.000 description 2
206010038910 Retinitis Diseases 0.000 description 2
241000710799 Rubella virus Species 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
235000021355 Stearic acid Nutrition 0.000 description 2
230000006044 T cell activation Effects 0.000 description 2
229960004150 aciclovir Drugs 0.000 description 2
MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 2
239000013543 active substance Substances 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
150000001338 aliphatic hydrocarbons Chemical class 0.000 description 2
208000026935 allergic disease Diseases 0.000 description 2
239000003708 ampul Substances 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
230000005875 antibody response Effects 0.000 description 2
230000000890 antigenic effect Effects 0.000 description 2
239000003443 antiviral agent Substances 0.000 description 2
125000003710 aryl alkyl group Chemical group 0.000 description 2
230000005784 autoimmunity Effects 0.000 description 2
239000002585 base Substances 0.000 description 2
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
230000005540 biological transmission Effects 0.000 description 2
229910002092 carbon dioxide Inorganic materials 0.000 description 2
239000005018 casein Substances 0.000 description 2
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
235000021240 caseins Nutrition 0.000 description 2
239000004359 castor oil Substances 0.000 description 2
235000019438 castor oil Nutrition 0.000 description 2
238000001516 cell proliferation assay Methods 0.000 description 2
229960002242 chlorocresol Drugs 0.000 description 2
230000007012 clinical effect Effects 0.000 description 2
238000011284 combination treatment Methods 0.000 description 2
238000012875 competitive assay Methods 0.000 description 2
229940104302 cytosine Drugs 0.000 description 2
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
230000034994 death Effects 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
239000006196 drop Substances 0.000 description 2
238000001035 drying Methods 0.000 description 2
241001493065 dsRNA viruses Species 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
201000005884 exanthem Diseases 0.000 description 2
238000001914 filtration Methods 0.000 description 2
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
238000009472 formulation Methods 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
210000003714 granulocyte Anatomy 0.000 description 2
231100000869 headache Toxicity 0.000 description 2
108060003552 hemocyanin Proteins 0.000 description 2
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 2
230000004727 humoral immunity Effects 0.000 description 2
230000005965 immune activity Effects 0.000 description 2
229940124589 immunosuppressive drug Drugs 0.000 description 2
230000001771 impaired effect Effects 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
229940047124 interferons Drugs 0.000 description 2
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
150000002576 ketones Chemical class 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
210000002540 macrophage Anatomy 0.000 description 2
239000012528 membrane Substances 0.000 description 2
229920000609 methyl cellulose Polymers 0.000 description 2
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
239000001923 methylcellulose Substances 0.000 description 2
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
239000003226 mitogen Substances 0.000 description 2
238000000465 moulding Methods 0.000 description 2
239000007923 nasal drop Substances 0.000 description 2
239000002777 nucleoside Substances 0.000 description 2
229940127073 nucleoside analogue Drugs 0.000 description 2
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
229940092253 ovalbumin Drugs 0.000 description 2
ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 2
FXLOVSHXALFLKQ-UHFFFAOYSA-N p-tolualdehyde Chemical compound CC1=CC=C(C=O)C=C1 FXLOVSHXALFLKQ-UHFFFAOYSA-N 0.000 description 2
239000002831 pharmacologic agent Substances 0.000 description 2
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
229940068977 polysorbate 20 Drugs 0.000 description 2
230000002028 premature Effects 0.000 description 2
230000008569 process Effects 0.000 description 2
206010037844 rash Diseases 0.000 description 2
230000009257 reactivity Effects 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
229940079832 sodium starch glycolate Drugs 0.000 description 2
229920003109 sodium starch glycolate Polymers 0.000 description 2
239000008109 sodium starch glycolate Substances 0.000 description 2
239000007787 solid Substances 0.000 description 2
238000004611 spectroscopical analysis Methods 0.000 description 2
239000007921 spray Substances 0.000 description 2
229940032147 starch Drugs 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000008117 stearic acid Substances 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
239000002511 suppository base Substances 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
229940104230 thymidine Drugs 0.000 description 2
238000013518 transcription Methods 0.000 description 2
230000035897 transcription Effects 0.000 description 2
241000712461 unidentified influenza virus Species 0.000 description 2
241001430294 unidentified retrovirus Species 0.000 description 2
201000001862 viral hepatitis Diseases 0.000 description 2
HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 2
GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
FTVWIRXFELQLPI-ZDUSSCGKSA-N (S)-naringenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 FTVWIRXFELQLPI-ZDUSSCGKSA-N 0.000 description 1
SICBLYCPRWNHHP-UHFFFAOYSA-N 1,2-bis(4-methoxyphenyl)ethanone Chemical compound C1=CC(OC)=CC=C1CC(=O)C1=CC=C(OC)C=C1 SICBLYCPRWNHHP-UHFFFAOYSA-N 0.000 description 1
DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
RBEXWVGCIBHYAD-HTQZYQBOSA-N 1-[(2r,5r)-4-hydroxy-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C(O)[C@@H](CO)O1 RBEXWVGCIBHYAD-HTQZYQBOSA-N 0.000 description 1
WVXRAFOPTSTNLL-NKWVEPMBSA-N 2',3'-dideoxyadenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1CC[C@@H](CO)O1 WVXRAFOPTSTNLL-NKWVEPMBSA-N 0.000 description 1
WWDIMPQSVRVLFI-UHFFFAOYSA-N 2-[(2-formyl-3-hydroxyphenoxy)methyl]benzoic acid Chemical compound OC(=O)C1=CC=CC=C1COC1=CC=CC(O)=C1C=O WWDIMPQSVRVLFI-UHFFFAOYSA-N 0.000 description 1
JCTYMCXPDPLZRY-UHFFFAOYSA-N 2-[butyl(hydroxymethyl)amino]-3,7-dihydropurin-6-one Chemical compound N1C(N(CO)CCCC)=NC(=O)C2=C1N=CN2 JCTYMCXPDPLZRY-UHFFFAOYSA-N 0.000 description 1
GHVNNICPZOBPSX-UHFFFAOYSA-N 2-hydroxy-6-[[4-(2h-tetrazol-5-yl)phenyl]methoxy]benzaldehyde Chemical compound OC1=CC=CC(OCC=2C=CC(=CC=2)C=2NN=NN=2)=C1C=O GHVNNICPZOBPSX-UHFFFAOYSA-N 0.000 description 1
239000001431 2-methylbenzaldehyde Substances 0.000 description 1
125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
208000010543 22q11.2 deletion syndrome Diseases 0.000 description 1
KCKZIWSINLBROE-UHFFFAOYSA-N 3,4-dihydro-1h-naphthalen-2-one Chemical compound C1=CC=C2CC(=O)CCC2=C1 KCKZIWSINLBROE-UHFFFAOYSA-N 0.000 description 1
XGCPUNMNOGIEFL-UHFFFAOYSA-N 3-(2-formyl-3-hydroxyphenoxy)propanenitrile Chemical compound OC1=CC=CC(OCCC#N)=C1C=O XGCPUNMNOGIEFL-UHFFFAOYSA-N 0.000 description 1
SLOWFFLRNJZBAZ-UHFFFAOYSA-N 3-[(2-formyl-3-hydroxyphenoxy)methyl]benzoic acid Chemical compound OC(=O)C1=CC=CC(COC=2C(=C(O)C=CC=2)C=O)=C1 SLOWFFLRNJZBAZ-UHFFFAOYSA-N 0.000 description 1
MPCYXHNZNVYCGK-OEJXEDHQSA-N 3-[(3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-prop-1-ynyl-1h-pyrimidine-2,4-dione Chemical compound O=C1C(C#CC)=CNC(=O)N1C1[C@@H](O)[C@H](O)[C@@H](CO)O1 MPCYXHNZNVYCGK-OEJXEDHQSA-N 0.000 description 1
QQUIWIVTEWQHKA-UHFFFAOYSA-N 3h-1,4-benzodiazepine Chemical compound C1=NCC=NC2=CC=CC=C21 QQUIWIVTEWQHKA-UHFFFAOYSA-N 0.000 description 1
KPACGYPPYXMYIQ-UHFFFAOYSA-N 4-(2-formyl-3-hydroxyphenoxy)butanoic acid Chemical compound OC(=O)CCCOC1=CC=CC(O)=C1C=O KPACGYPPYXMYIQ-UHFFFAOYSA-N 0.000 description 1
SSKKREZNXCEIJS-UHFFFAOYSA-N 4-[(3-acetamido-2-formylphenoxy)methyl]benzoic acid Chemical compound CC(=O)NC1=CC=CC(OCC=2C=CC(=CC=2)C(O)=O)=C1C=O SSKKREZNXCEIJS-UHFFFAOYSA-N 0.000 description 1
XQSPYNMVSIKCOC-RITPCOANSA-N 4-amino-5-fluoro-1-[(2s,5r)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one Chemical compound C1=C(F)C(N)=NC(=O)N1[C@@H]1O[C@H](CO)SC1 XQSPYNMVSIKCOC-RITPCOANSA-N 0.000 description 1
AVPYQKSLYISFPO-UHFFFAOYSA-N 4-chlorobenzaldehyde Chemical compound ClC1=CC=C(C=O)C=C1 AVPYQKSLYISFPO-UHFFFAOYSA-N 0.000 description 1
UWDMKTDPDJCJOP-UHFFFAOYSA-N 4-hydroxy-2,2,6,6-tetramethylpiperidin-1-ium-4-carboxylate Chemical compound CC1(C)CC(O)(C(O)=O)CC(C)(C)N1 UWDMKTDPDJCJOP-UHFFFAOYSA-N 0.000 description 1
CUODMIIQLQAICS-UHFFFAOYSA-N 4-hydroxy-5-(4-methoxyphenyl)pent-3-en-2-one Chemical compound COC1=CC=C(CC(O)=CC(C)=O)C=C1 CUODMIIQLQAICS-UHFFFAOYSA-N 0.000 description 1
BXRFQSNOROATLV-UHFFFAOYSA-N 4-nitrobenzaldehyde Chemical compound [O-][N+](=O)C1=CC=C(C=O)C=C1 BXRFQSNOROATLV-UHFFFAOYSA-N 0.000 description 1
VXEVAZSHSAXJNH-UHFFFAOYSA-N 5-(2-formyl-3-hydroxy-4-methoxyphenoxy)pentanoic acid Chemical compound COC1=CC=C(OCCCCC(O)=O)C(C=O)=C1O VXEVAZSHSAXJNH-UHFFFAOYSA-N 0.000 description 1
VFKFAELUHMKKKB-UHFFFAOYSA-N 5-(2-formyl-3-hydroxy-4-propoxyphenoxy)pentanoic acid Chemical compound CCCOC1=CC=C(OCCCCC(O)=O)C(C=O)=C1O VFKFAELUHMKKKB-UHFFFAOYSA-N 0.000 description 1
XPKJLBBVFHFSEM-UHFFFAOYSA-N 5-(2-formyl-3-hydroxyphenoxy)-2,2-dimethylpentanoic acid Chemical compound OC(=O)C(C)(C)CCCOC1=CC=CC(O)=C1C=O XPKJLBBVFHFSEM-UHFFFAOYSA-N 0.000 description 1
QYLSCHCZGSONML-UHFFFAOYSA-N 5-(2-formyl-3-hydroxyphenoxy)-2-methylpentanoic acid Chemical compound OC(=O)C(C)CCCOC1=CC=CC(O)=C1C=O QYLSCHCZGSONML-UHFFFAOYSA-N 0.000 description 1
KBWBGANILAOXHI-UHFFFAOYSA-N 5-(2-formyl-3-hydroxyphenoxy)-n-methylsulfonylpentanamide Chemical compound CS(=O)(=O)NC(=O)CCCCOC1=CC=CC(O)=C1C=O KBWBGANILAOXHI-UHFFFAOYSA-N 0.000 description 1
URGSRYJANOBLBB-UHFFFAOYSA-N 5-(2-formyl-3-hydroxyphenoxy)-n-propan-2-ylpentanamide Chemical compound CC(C)NC(=O)CCCCOC1=CC=CC(O)=C1C=O URGSRYJANOBLBB-UHFFFAOYSA-N 0.000 description 1
FRXRLTATMMDVNZ-UHFFFAOYSA-N 5-(2-formyl-3-hydroxyphenoxy)pentanamide Chemical compound NC(=O)CCCCOC1=CC=CC(O)=C1C=O FRXRLTATMMDVNZ-UHFFFAOYSA-N 0.000 description 1
FYUSDHGUBKZBON-UHFFFAOYSA-N 5-(2-formyl-3-hydroxyphenoxy)pentanenitrile Chemical compound OC1=CC=CC(OCCCCC#N)=C1C=O FYUSDHGUBKZBON-UHFFFAOYSA-N 0.000 description 1
JLGXUFPZHQHMKN-UHFFFAOYSA-N 5-(3-acetamido-2-formylphenoxy)pentanoic acid Chemical compound CC(=O)NC1=CC=CC(OCCCCC(O)=O)=C1C=O JLGXUFPZHQHMKN-UHFFFAOYSA-N 0.000 description 1
IUFNEZRKCZYFSG-UHFFFAOYSA-N 5-(4,6-dichloro-2-formyl-3-hydroxyphenoxy)pentanoic acid Chemical compound OC(=O)CCCCOC1=C(Cl)C=C(Cl)C(O)=C1C=O IUFNEZRKCZYFSG-UHFFFAOYSA-N 0.000 description 1
AEYWTWGAFMYRFW-UHFFFAOYSA-N 5-(4-chloro-2-formyl-3-hydroxyphenoxy)pentanoic acid Chemical compound OC(=O)CCCCOC1=CC=C(Cl)C(O)=C1C=O AEYWTWGAFMYRFW-UHFFFAOYSA-N 0.000 description 1
WKVDSZYIGHLONN-RRKCRQDMSA-N 5-chloro-1-[(2r,4s,5r)-4-fluoro-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione Chemical compound C1[C@H](F)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Cl)=C1 WKVDSZYIGHLONN-RRKCRQDMSA-N 0.000 description 1
POYNHVFBISCPAG-DJLDLDEBSA-N 5-ethynyl-1-[(2r,4s,5r)-4-fluoro-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione Chemical compound C1[C@H](F)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C#C)=C1 POYNHVFBISCPAG-DJLDLDEBSA-N 0.000 description 1
FHIDNBAQOFJWCA-UAKXSSHOSA-N 5-fluorouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 FHIDNBAQOFJWCA-UAKXSSHOSA-N 0.000 description 1
POUITAHNNRJWMA-UHFFFAOYSA-N 5-hydroxybenzofuran-2-one Chemical compound OC1=CC=C2OC(=O)CC2=C1 POUITAHNNRJWMA-UHFFFAOYSA-N 0.000 description 1
BRCPWISABURVIH-UHFFFAOYSA-N 5-methoxy-3,4-dihydro-2h-naphthalen-1-one Chemical compound O=C1CCCC2=C1C=CC=C2OC BRCPWISABURVIH-UHFFFAOYSA-N 0.000 description 1
KJPMWVKPVCVZNK-UHFFFAOYSA-N 6,7-dimethoxy-3,4-dihydro-1h-naphthalen-2-one Chemical compound C1CC(=O)CC2=C1C=C(OC)C(OC)=C2 KJPMWVKPVCVZNK-UHFFFAOYSA-N 0.000 description 1
QYQYFTULSFTJRU-UHFFFAOYSA-N 6-(2-formyl-3-hydroxyphenoxy)hexanoic acid Chemical compound OC(=O)CCCCCOC1=CC=CC(O)=C1C=O QYQYFTULSFTJRU-UHFFFAOYSA-N 0.000 description 1
IRUHWRSITUYICV-UHFFFAOYSA-N 6-hydroxy-4-methylchromen-2-one Chemical compound C1=CC(O)=CC2=C1OC(=O)C=C2C IRUHWRSITUYICV-UHFFFAOYSA-N 0.000 description 1
CQWXLWDPFSPVHK-UHFFFAOYSA-N 6-hydroxynaphthalene-1,2-dione Chemical compound O=C1C(=O)C=CC2=CC(O)=CC=C21 CQWXLWDPFSPVHK-UHFFFAOYSA-N 0.000 description 1
MNALUTYMBUBKNX-UHFFFAOYSA-N 6-methoxy-3,4-dihydro-2h-naphthalen-1-one Chemical compound O=C1CCCC2=CC(OC)=CC=C21 MNALUTYMBUBKNX-UHFFFAOYSA-N 0.000 description 1
DGVPMYXLJJNSOU-UHFFFAOYSA-N 7-(2-formyl-3-hydroxyphenoxy)heptanoic acid Chemical compound OC(=O)CCCCCCOC1=CC=CC(O)=C1C=O DGVPMYXLJJNSOU-UHFFFAOYSA-N 0.000 description 1
XEAPZXNZOJGVCZ-UHFFFAOYSA-N 7-methoxy-3,4-dihydro-1h-naphthalen-2-one Chemical compound C1CC(=O)CC2=CC(OC)=CC=C21 XEAPZXNZOJGVCZ-UHFFFAOYSA-N 0.000 description 1
GABLTKRIYDNDIN-UHFFFAOYSA-N 7-methoxy-3,4-dihydro-2h-naphthalen-1-one Chemical compound C1CCC(=O)C2=CC(OC)=CC=C21 GABLTKRIYDNDIN-UHFFFAOYSA-N 0.000 description 1
NUJXPZCMZLDPOM-UHFFFAOYSA-N 8,10-dioxoundecanoic acid Chemical compound CC(=O)CC(=O)CCCCCCC(O)=O NUJXPZCMZLDPOM-UHFFFAOYSA-N 0.000 description 1
BTYBORAHYUCUMH-UHFFFAOYSA-N 8-methoxy-3,4-dihydro-1h-naphthalen-2-one Chemical compound C1CC(=O)CC2=C1C=CC=C2OC BTYBORAHYUCUMH-UHFFFAOYSA-N 0.000 description 1
208000004998 Abdominal Pain Diseases 0.000 description 1
206010067484 Adverse reaction Diseases 0.000 description 1
UXCAQJAQSWSNPQ-XLPZGREQSA-N Alovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](F)C1 UXCAQJAQSWSNPQ-XLPZGREQSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
241000712891 Arenavirus Species 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
108090001008 Avidin Proteins 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
201000004569 Blindness Diseases 0.000 description 1
208000011691 Burkitt lymphomas Diseases 0.000 description 1
208000002177 Cataract Diseases 0.000 description 1
201000006082 Chickenpox Diseases 0.000 description 1
206010008909 Chronic Hepatitis Diseases 0.000 description 1
108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
206010010071 Coma Diseases 0.000 description 1
206010062343 Congenital infection Diseases 0.000 description 1
206010010904 Convulsion Diseases 0.000 description 1
241000450599 DNA viruses Species 0.000 description 1
206010011968 Decreased immune responsiveness Diseases 0.000 description 1
208000000398 DiGeorge Syndrome Diseases 0.000 description 1
241000709661 Enterovirus Species 0.000 description 1
206010015108 Epstein-Barr virus infection Diseases 0.000 description 1
208000001860 Eye Infections Diseases 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
229920001917 Ficoll Polymers 0.000 description 1
206010017533 Fungal infection Diseases 0.000 description 1
241000233866 Fungi Species 0.000 description 1
208000018522 Gastrointestinal disease Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
241000941423 Grom virus Species 0.000 description 1
208000005794 Hairy Leukoplakia Diseases 0.000 description 1
208000005331 Hepatitis D Diseases 0.000 description 1
206010019755 Hepatitis chronic active Diseases 0.000 description 1
208000029433 Herpesviridae infectious disease Diseases 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical group C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
206010053574 Immunoblastic lymphoma Diseases 0.000 description 1
206010061217 Infestation Diseases 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
241001500351 Influenzavirus A Species 0.000 description 1
102000000588 Interleukin-2 Human genes 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
UKIYDXCFKFLIMU-UHFFFAOYSA-M Isopaque Chemical compound [Na+].CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I UKIYDXCFKFLIMU-UHFFFAOYSA-M 0.000 description 1
206010023126 Jaundice Diseases 0.000 description 1
PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
125000002061 L-isoleucyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](C([H])([H])[H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
125000003580 L-valyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(C([H])([H])[H])(C([H])([H])[H])[H] 0.000 description 1
206010024229 Leprosy Diseases 0.000 description 1
206010024971 Lower respiratory tract infections Diseases 0.000 description 1
208000008771 Lymphadenopathy Diseases 0.000 description 1
241000712079 Measles morbillivirus Species 0.000 description 1
208000036626 Mental retardation Diseases 0.000 description 1
229920001410 Microfiber Polymers 0.000 description 1
241001430197 Mollicutes Species 0.000 description 1
241000711386 Mumps virus Species 0.000 description 1
206010028470 Mycoplasma infections Diseases 0.000 description 1
208000031888 Mycoses Diseases 0.000 description 1
208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
208000012902 Nervous system disease Diseases 0.000 description 1
208000025966 Neurological disease Diseases 0.000 description 1
208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
102000011931 Nucleoproteins Human genes 0.000 description 1
108010061100 Nucleoproteins Proteins 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
208000005141 Otitis Diseases 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
241001631646 Papillomaviridae Species 0.000 description 1
229930040373 Paraformaldehyde Natural products 0.000 description 1
208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 description 1
241000709664 Picornaviridae Species 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
206010037742 Rabies Diseases 0.000 description 1
206010038389 Renal cancer Diseases 0.000 description 1
208000006265 Renal cell carcinoma Diseases 0.000 description 1
241000725643 Respiratory syncytial virus Species 0.000 description 1
IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
XWNMORIHKRROGW-UHFFFAOYSA-N Ro 5-3335 Chemical compound C12=CC(Cl)=CC=C2NC(=O)CN=C1C1=CC=CN1 XWNMORIHKRROGW-UHFFFAOYSA-N 0.000 description 1
241000702670 Rotavirus Species 0.000 description 1
241000700584 Simplexvirus Species 0.000 description 1
108010021119 Trichosanthin Proteins 0.000 description 1
206010046980 Varicella Diseases 0.000 description 1
108020005202 Viral DNA Proteins 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
MULRMTLVICSWMO-JCKUYFFHSA-N [(z)-octadec-9-enyl] (2s)-2-acetamido-5-amino-5-oxopentanoate Chemical compound CCCCCCCC\C=C/CCCCCCCCOC(=O)[C@@H](NC(C)=O)CCC(N)=O MULRMTLVICSWMO-JCKUYFFHSA-N 0.000 description 1
210000001015 abdomen Anatomy 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
229960004308 acetylcysteine Drugs 0.000 description 1
230000006838 adverse reaction Effects 0.000 description 1
239000004479 aerosol dispenser Substances 0.000 description 1
QNHQEUFMIKRNTB-UHFFFAOYSA-N aesculetin Natural products C1CC(=O)OC2=C1C=C(O)C(O)=C2 QNHQEUFMIKRNTB-UHFFFAOYSA-N 0.000 description 1
150000001299 aldehydes Chemical class 0.000 description 1
125000003282 alkyl amino group Chemical group 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
230000007815 allergy Effects 0.000 description 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
208000022531 anorexia Diseases 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000003005 anticarcinogenic agent Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
238000003782 apoptosis assay Methods 0.000 description 1
150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
238000003556 assay Methods 0.000 description 1
238000000889 atomisation Methods 0.000 description 1
230000001363 autoimmune Effects 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
230000008901 benefit Effects 0.000 description 1
GVQLLDWWYDKCAL-UHFFFAOYSA-N benzyl 5-(2-formyl-3-hydroxyphenoxy)pentanoate Chemical compound OC1=CC=CC(OCCCCC(=O)OCC=2C=CC=CC=2)=C1C=O GVQLLDWWYDKCAL-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
229960002685 biotin Drugs 0.000 description 1
239000011616 biotin Substances 0.000 description 1
201000008275 breast carcinoma Diseases 0.000 description 1
239000012267 brine Substances 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000004067 bulking agent Substances 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000007969 cellular immunity Effects 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
208000019065 cervical carcinoma Diseases 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
210000000038 chest Anatomy 0.000 description 1
230000007882 cirrhosis Effects 0.000 description 1
208000019425 cirrhosis of liver Diseases 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
201000010897 colon adenocarcinoma Diseases 0.000 description 1
208000029742 colonic neoplasm Diseases 0.000 description 1
229940047120 colony stimulating factors Drugs 0.000 description 1
229940125904 compound 1 Drugs 0.000 description 1
229940125797 compound 12 Drugs 0.000 description 1
239000007891 compressed tablet Substances 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
238000006482 condensation reaction Methods 0.000 description 1
239000000470 constituent Substances 0.000 description 1
239000013068 control sample Substances 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
239000012050 conventional carrier Substances 0.000 description 1
230000036461 convulsion Effects 0.000 description 1
108091008034 costimulatory receptors Proteins 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
230000006378 damage Effects 0.000 description 1
206010061428 decreased appetite Diseases 0.000 description 1
230000008260 defense mechanism Effects 0.000 description 1
239000003405 delayed action preparation Substances 0.000 description 1
238000000432 density-gradient centrifugation Methods 0.000 description 1
230000005595 deprotonation Effects 0.000 description 1
238000010537 deprotonation reaction Methods 0.000 description 1
229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
229960002768 dipyridamole Drugs 0.000 description 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
231100000676 disease causative agent Toxicity 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
208000019258 ear infection Diseases 0.000 description 1
ILEDWLMCKZNDJK-UHFFFAOYSA-N esculetin Chemical compound C1=CC(=O)OC2=C1C=C(O)C(O)=C2 ILEDWLMCKZNDJK-UHFFFAOYSA-N 0.000 description 1
QEGWIXJLDSHEIN-UHFFFAOYSA-N ethyl 4-[(3-acetamido-2-formylphenoxy)methyl]benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1COC1=CC=CC(NC(C)=O)=C1C=O QEGWIXJLDSHEIN-UHFFFAOYSA-N 0.000 description 1
PVPWPJFEUIVMSW-UHFFFAOYSA-N ethyl 5-(2-formyl-3-hydroxyphenoxy)pentanoate Chemical compound CCOC(=O)CCCCOC1=CC=CC(O)=C1C=O PVPWPJFEUIVMSW-UHFFFAOYSA-N 0.000 description 1
230000029142 excretion Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
230000004438 eyesight Effects 0.000 description 1
230000008175 fetal development Effects 0.000 description 1
239000000945 filler Substances 0.000 description 1
238000011049 filling Methods 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
229960004413 flucytosine Drugs 0.000 description 1
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
239000012634 fragment Substances 0.000 description 1
206010017758 gastric cancer Diseases 0.000 description 1
208000010749 gastric carcinoma Diseases 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
230000008570 general process Effects 0.000 description 1
210000004392 genitalia Anatomy 0.000 description 1
210000004195 gingiva Anatomy 0.000 description 1
230000012010 growth Effects 0.000 description 1
201000003911 head and neck carcinoma Diseases 0.000 description 1
201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 1
208000005252 hepatitis A Diseases 0.000 description 1
206010073071 hepatocellular carcinoma Diseases 0.000 description 1
231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
206010019847 hepatosplenomegaly Diseases 0.000 description 1
230000009215 host defense mechanism Effects 0.000 description 1
150000002430 hydrocarbons Chemical group 0.000 description 1
125000004356 hydroxy functional group Chemical group O* 0.000 description 1
238000012744 immunostaining Methods 0.000 description 1
229940125721 immunosuppressive agent Drugs 0.000 description 1
238000002513 implantation Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
239000012678 infectious agent Substances 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
201000006747 infectious mononucleosis Diseases 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
230000009545 invasion Effects 0.000 description 1
238000006317 isomerization reaction Methods 0.000 description 1
206010023332 keratitis Diseases 0.000 description 1
229940041476 lactose 100 mg Drugs 0.000 description 1
201000005264 laryngeal carcinoma Diseases 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
201000007270 liver cancer Diseases 0.000 description 1
208000019423 liver disease Diseases 0.000 description 1
208000014018 liver neoplasm Diseases 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
206010025482 malaise Diseases 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
230000008774 maternal effect Effects 0.000 description 1
238000005259 measurement Methods 0.000 description 1
101150025474 mecr gene Proteins 0.000 description 1
238000002483 medication Methods 0.000 description 1
239000002609 medium Substances 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
JUXODYXAYBHXFN-UHFFFAOYSA-N methyl 3-[(2-formyl-3-hydroxyphenoxy)methyl]benzoate Chemical compound COC(=O)C1=CC=CC(COC=2C(=C(O)C=CC=2)C=O)=C1 JUXODYXAYBHXFN-UHFFFAOYSA-N 0.000 description 1
FEIOASZZURHTHB-UHFFFAOYSA-N methyl 4-formylbenzoate Chemical compound COC(=O)C1=CC=C(C=O)C=C1 FEIOASZZURHTHB-UHFFFAOYSA-N 0.000 description 1
239000003658 microfiber Substances 0.000 description 1
239000003595 mist Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
239000007932 molded tablet Substances 0.000 description 1
210000005087 mononuclear cell Anatomy 0.000 description 1
JPSAMYBDBKJMPH-UHFFFAOYSA-N n,n-diethyl-5-(2-formyl-3-hydroxyphenoxy)pentanamide Chemical compound CCN(CC)C(=O)CCCCOC1=CC=CC(O)=C1C=O JPSAMYBDBKJMPH-UHFFFAOYSA-N 0.000 description 1
150000002791 naphthoquinones Chemical group 0.000 description 1
229940117954 naringenin Drugs 0.000 description 1
WGEYAGZBLYNDFV-UHFFFAOYSA-N naringenin Natural products C1(=O)C2=C(O)C=C(O)C=C2OC(C1)C1=CC=C(CC1)O WGEYAGZBLYNDFV-UHFFFAOYSA-N 0.000 description 1
235000007625 naringenin Nutrition 0.000 description 1
210000003928 nasal cavity Anatomy 0.000 description 1
230000008693 nausea Effects 0.000 description 1
230000009826 neoplastic cell growth Effects 0.000 description 1
230000001613 neoplastic effect Effects 0.000 description 1
210000003061 neural cell Anatomy 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
210000001331 nose Anatomy 0.000 description 1
230000000269 nucleophilic effect Effects 0.000 description 1
150000003833 nucleoside derivatives Chemical class 0.000 description 1
239000003921 oil Substances 0.000 description 1
238000006213 oxygenation reaction Methods 0.000 description 1
SEVSMVUOKAMPDO-UHFFFAOYSA-N para-Acetoxybenzaldehyde Natural products CC(=O)OC1=CC=C(C=O)C=C1 SEVSMVUOKAMPDO-UHFFFAOYSA-N 0.000 description 1
229920002866 paraformaldehyde Polymers 0.000 description 1
244000045947 parasite Species 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000013618 particulate matter Substances 0.000 description 1
XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 description 1
229960004448 pentamidine Drugs 0.000 description 1
TZMFJUDUGYTVRY-UHFFFAOYSA-N pentane-2,3-dione Chemical compound CCC(=O)C(C)=O TZMFJUDUGYTVRY-UHFFFAOYSA-N 0.000 description 1
229960001476 pentoxifylline Drugs 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
239000011148 porous material Substances 0.000 description 1
230000035935 pregnancy Effects 0.000 description 1
208000037920 primary disease Diseases 0.000 description 1
DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
229960003081 probenecid Drugs 0.000 description 1
239000000047 product Substances 0.000 description 1
230000005522 programmed cell death Effects 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
235000018102 proteins Nutrition 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
230000005588 protonation Effects 0.000 description 1
HYHBKLWDTGTBME-UHFFFAOYSA-N pyrazin-1-ium;chloride Chemical compound Cl.C1=CN=CC=N1 HYHBKLWDTGTBME-UHFFFAOYSA-N 0.000 description 1
230000000637 radiosensitizating effect Effects 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
206010038038 rectal cancer Diseases 0.000 description 1
208000020615 rectal carcinoma Diseases 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
201000010174 renal carcinoma Diseases 0.000 description 1
230000008439 repair process Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
229960000329 ribavirin Drugs 0.000 description 1
HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
208000007442 rickets Diseases 0.000 description 1
239000000523 sample Substances 0.000 description 1
QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
230000011664 signaling Effects 0.000 description 1
231100000046 skin rash Toxicity 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
235000002639 sodium chloride Nutrition 0.000 description 1
YEENEYXBHNNNGV-XEHWZWQGSA-M sodium;3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoate;(2r,3r,4s,5s,6r)-2-[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound [Na+].CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I.O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 YEENEYXBHNNNGV-XEHWZWQGSA-M 0.000 description 1
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
230000000707 stereoselective effect Effects 0.000 description 1
201000000498 stomach carcinoma Diseases 0.000 description 1
229960005404 sulfamethoxazole Drugs 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
201000000596 systemic lupus erythematosus Diseases 0.000 description 1
150000003536 tetrazoles Chemical class 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
239000003104 tissue culture media Substances 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
238000013519 translation Methods 0.000 description 1
229940029284 trichlorofluoromethane Drugs 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
201000008827 tuberculosis Diseases 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
239000012646 vaccine adjuvant Substances 0.000 description 1
229940124931 vaccine adjuvant Drugs 0.000 description 1
244000052613 viral pathogen Species 0.000 description 1
230000008673 vomiting Effects 0.000 description 1
235000012431 wafers Nutrition 0.000 description 1
238000005303 weighing Methods 0.000 description 1
229960002555 zidovudine Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/11—Aldehydes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A61K31/37—Coumarins, e.g. psoralen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Emergency Medicine (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Oncology (AREA)
Gastroenterology & Hepatology (AREA)
Communicable Diseases (AREA)
Virology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Planar Illumination Modules (AREA)
Illuminated Signs And Luminous Advertising (AREA)
Securing Globes, Refractors, Reflectors Or The Like (AREA)

SI9300514A 1992-10-01 1993-09-30 Immunopotentiatory agent and physiologically acceptable salts thereof SI9300514A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB929220715A GB9220715D0 (en)	1992-10-01	1992-10-01	Immunopotentiatory agent and physiologically acceptable salts thereof
GB929226874A GB9226874D0 (en)	1992-12-23	1992-12-23	Immunopotentiatory agents and physiologically acceptable salts thereof

Publications (1)

Publication Number	Publication Date
SI9300514A true SI9300514A (en)	1994-06-30

Family

ID=26301715

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SI9300514A SI9300514A (en)	1992-10-01	1993-09-30	Immunopotentiatory agent and physiologically acceptable salts thereof

Country Status (24)

Country	Link
US (1)	US5508310A (2)
EP (3)	EP0678298A3 (2)
JP (2)	JP3717950B2 (2)
KR (1)	KR100348775B1 (2)
CN (1)	CN1213746C (2)
AT (1)	ATE146075T1 (2)
AU (1)	AU676491B2 (2)
CA (1)	CA2124677C (2)
CZ (1)	CZ132794A3 (2)
DE (1)	DE69306545T2 (2)
DK (1)	DK0609606T3 (2)
ES (1)	ES2096215T3 (2)
GR (1)	GR3022541T3 (2)
HR (1)	HRP931243A2 (2)
HU (1)	HUT70482A (2)
IL (1)	IL107157A0 (2)
MX (1)	MX9306079A (2)
NZ (1)	NZ256110A (2)
RU (1)	RU94028670A (2)
SG (1)	SG48993A1 (2)
SI (1)	SI9300514A (2)
SK (1)	SK65294A3 (2)
WO (1)	WO1994007479A2 (2)
YU (1)	YU62793A (2)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU3539795A (en) *	1994-08-25	1996-03-14	Medical University Of South Carolina	Methods of treating cold symptoms using pentoxifylline
GB9601544D0 (en) *	1996-01-26	1996-03-27	Smithkline Beecham Plc	Pharmaceuticals
BR9809149A (pt) *	1997-05-20	2000-08-01	Galenica Pharmaceuticals Inc	Análogos de triterpeno saponina dotados de adjuvante e atividade imonoestimulatória
US6080725A (en) *	1997-05-20	2000-06-27	Galenica Pharmaceuticals, Inc.	Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
ES2245805T3 (es) *	1997-10-03	2006-01-16	Galenica Pharmaceuticals, Inc.	Polisacaridos que forman iminas, preparacion de los mismos y el uso de los mismos como adyuvantes de inmunoestimulantes.
WO2000009075A2 (en)	1998-08-14	2000-02-24	Galenica Pharmaceuticals, Inc.	Chemically modified saponins and the use thereof as adjuvants
GB9818627D0 (en) *	1998-08-26	1998-10-21	Glaxo Group Ltd	Improvements in dva vaccination
US6939896B2 (en) *	1999-12-21	2005-09-06	Astrazeneca Ab	Cd45 inhibitors
JP2003518085A (ja) *	1999-12-21	2003-06-03	アストラゼネカアクチボラグ	Ｃｄ４５阻害剤
US7638496B2 (en)	2000-02-15	2009-12-29	Valeant Pharmaceuticals North America	Nucleoside analogs with carboxamidine modified monocyclic base
AU2001245823A1 (en) *	2000-03-17	2001-10-03	Corixa Corporation	Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors
PL211872B1 (pl)	2000-03-31	2012-07-31	Purdue Research Foundation	Kompozycja farmaceutyczna
AU2001251491A1 (en) *	2000-04-11	2001-10-23	Galenica Pharmaceuticals, Inc.	Lipophilic aromatic aldehyde and ketone derivatives and the use thereof as immunostimulants and adjuvants
CA2445826C (en) *	2001-05-02	2014-03-25	Purdue Research Foundation	Treatment and diagnosis of macrophage mediated disease
KR20040053136A (ko) *	2001-09-28	2004-06-23	펄듀 리서치 파운데이션	리간드-면역원 공액체를 이용한 치료 방법
US8246969B2 (en)	2001-11-16	2012-08-21	Skinmedica, Inc.	Compositions containing aromatic aldehydes and their use in treatments
US20030157154A1 (en) *	2002-01-04	2003-08-21	Bryan Fuller	Compositions containing hydroxy aromatic aldehydes and their use in treatments
US6911434B2 (en) *	2002-02-04	2005-06-28	Corixa Corporation	Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds
WO2004028470A2 (en) *	2002-09-27	2004-04-08	Martek Biosciences Corporation	Prophylactic docosahexaenoic acid therapy for patients with subclinical inflammation
EP1622554A4 (en) *	2003-05-15	2008-01-02	Bioform Medical Inc	COMPOSITIONS CONTAINING A COMBINATION OF A PHARMACEUTICAL AGENT OR A COSMETIC AGENT AND AN OXY-GROUP-WEARING AROMATIC ALDEHYDE
KR20050118057A (ko) *	2004-04-24	2005-12-15	김상희	아세틸디아실글리세롤류의 화합물을 유효성분으로함유하는 항암제 및 건강식품
US7622128B2 (en) *	2005-12-13	2009-11-24	University Of Washington	Porphyromonas gingivalis 1435/1449 LPS as an immune modulator
US8168164B2 (en) *	2006-02-03	2012-05-01	Purdue Research Foundation	Targeted conjugates and radiation
JP5554713B2 (ja) *	2007-11-15	2014-07-23	エンドサイト，インク．	接合体を投与する方法
EP2661264B1 (en)	2011-01-07	2018-12-05	Allergan, Inc.	Melanin modification compositions and methods of use
MX383691B (es)	2015-03-06	2025-03-14	Beyondspring Pharmaceuticals Inc	Método de tratamiento de cáncer asociado con una mutación de ras.
US10155748B2 (en)	2015-07-13	2018-12-18	Beyondspring Pharmaceuticals, Inc.	Plinabulin compositions
WO2017139231A1 (en)	2016-02-08	2017-08-17	Beyondspring Pharmaceuticals, Inc.	Compositions containing tucaresol or its analogs
RU2760348C2 (ru)	2016-06-06	2021-11-24	Бейондспринг Фармасьютикалс, Инк.	Способ уменьшения нейтропении
JP2020503363A (ja)	2017-01-06	2020-01-30	ビヨンドスプリングファーマシューティカルズ，インコーポレイテッド	チューブリン結合化合物およびその治療的使用
BR112019015974A2 (pt)	2017-02-01	2020-03-31	Beyondspring Pharmaceuticals, Inc.	Método para reduzir neutropenia
KR20200112881A (ko)	2018-01-24	2020-10-05	비욘드스프링 파마수티컬스, 인코포레이티드.	플리나불린의 투여를 통해 혈소판감소증을 감소시키는 조성물 및 방법
CA3215047A1 (en)	2021-04-09	2022-10-13	Lan Huang	Therapeutic compositions and methods for treating tumors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS54126731A (en) *	1978-03-20	1979-10-02	Rikagaku Kenkyusho	Carcinostatic agent
JPS5545658A (en) *	1978-09-28	1980-03-31	Rikagaku Kenkyusho	Carcinostatic agent
JPS5569510A (en) *	1978-11-16	1980-05-26	Mitsubishi Chem Ind Ltd	Carcinostatic agent
IT1193786B (it) *	1980-12-18	1988-08-24	Wellcome Found	Composti eterei dotati di attivita' mitigatrice delle emoglobinopatie intermedi e procedimento per la loro preparazione
LU85365A1 (de) *	1984-05-16	1986-01-29	Chimicasa Gmbh	Verfahren und praeparat zur stimulierung des immunsystems
DE3431236A1 (de) *	1984-08-24	1986-02-27	Carnivora-Deutschland GmbH, 7109 Jagsthausen	Verwendung von 1,4-naphthochinon-derivaten in niedrigen konzentrationen zur immunstimulation
DE3528709A1 (de) *	1985-08-09	1987-02-19	Schleicher Peter	Mundpflegemittel
JPS63264409A (ja) *	1988-01-13	1988-11-01	Rikagaku Kenkyusho	制癌剤
JPH03254007A (ja) *	1990-03-01	1991-11-13	Tir Syst Ltd	非吸収性で且つ透過率が可変のカバーを有した照明装置
GB9018061D0 (en) *	1990-08-17	1990-10-03	Wellcome Found	Compositions for vaccines
EP0499015A1 (en) *	1991-02-15	1992-08-19	Fockerman, Jasmine	Benzopyran phenol derivates for use as antibacterial, antiviral or immunostimulating agents

1993
- 1993-09-17 DE DE69306545T patent/DE69306545T2/de not_active Expired - Lifetime
- 1993-09-17 DK DK93307373.6T patent/DK0609606T3/da active
- 1993-09-17 ES ES93307373T patent/ES2096215T3/es not_active Expired - Lifetime
- 1993-09-17 AT AT93307373T patent/ATE146075T1/de not_active IP Right Cessation
- 1993-09-17 EP EP95110267A patent/EP0678298A3/en not_active Withdrawn
- 1993-09-17 SG SG1996004981A patent/SG48993A1/en unknown
- 1993-09-17 EP EP93307373A patent/EP0609606B1/en not_active Expired - Lifetime
- 1993-09-29 IL IL107157A patent/IL107157A0/xx unknown
- 1993-09-30 KR KR1019940701840A patent/KR100348775B1/ko not_active Expired - Fee Related
- 1993-09-30 HR HR931243A patent/HRP931243A2/hr not_active Application Discontinuation
- 1993-09-30 RU RU94028670/14A patent/RU94028670A/ru unknown
- 1993-09-30 JP JP27730093A patent/JP3717950B2/ja not_active Expired - Fee Related
- 1993-09-30 MX MX9306079A patent/MX9306079A/es unknown
- 1993-09-30 NZ NZ256110A patent/NZ256110A/en unknown
- 1993-09-30 CN CNB931144442A patent/CN1213746C/zh not_active Expired - Fee Related
- 1993-09-30 WO PCT/GB1993/002039 patent/WO1994007479A2/en not_active Ceased
- 1993-09-30 EP EP93921034A patent/EP0614357A1/en not_active Withdrawn
- 1993-09-30 SK SK652-94A patent/SK65294A3/sk unknown
- 1993-09-30 JP JP6508846A patent/JPH07504204A/ja not_active Withdrawn
- 1993-09-30 HU HU9401631A patent/HUT70482A/hu unknown
- 1993-09-30 YU YU62793A patent/YU62793A/sh unknown
- 1993-09-30 CZ CZ941327A patent/CZ132794A3/cs unknown
- 1993-09-30 AU AU48311/93A patent/AU676491B2/en not_active Ceased
- 1993-09-30 SI SI9300514A patent/SI9300514A/sl unknown
- 1993-09-30 CA CA002124677A patent/CA2124677C/en not_active Expired - Fee Related
1995
- 1995-05-19 US US08/446,080 patent/US5508310A/en not_active Expired - Fee Related
1997
- 1997-02-12 GR GR970400229T patent/GR3022541T3/el unknown

Also Published As

Publication number	Publication date
GR3022541T3 (en)	1997-05-31
JP3717950B2 (ja)	2005-11-16
DE69306545D1 (de)	1997-01-23
CA2124677A1 (en)	1994-04-14
ES2096215T3 (es)	1997-03-01
US5508310A (en)	1996-04-16
NZ256110A (en)	1997-07-27
DE69306545T2 (de)	1997-04-03
EP0614357A1 (en)	1994-09-14
RU94028670A (ru)	1996-05-20
WO1994007479A3 (en)	1994-07-21
CN1213746C (zh)	2005-08-10
EP0678298A3 (en)	1996-05-29
CZ132794A3 (en)	1995-02-15
DK0609606T3 (2)	1997-03-17
MX9306079A (es)	1994-06-30
AU4831193A (en)	1994-04-26
YU62793A (sh)	1998-05-15
SG48993A1 (en)	1998-05-18
WO1994007479A2 (en)	1994-04-14
EP0678298A2 (en)	1995-10-25
JPH072660A (ja)	1995-01-06
HRP931243A2 (en)	1995-12-31
AU676491B2 (en)	1997-03-13
IL107157A0 (en)	1993-12-28
EP0609606B1 (en)	1996-12-11
HUT70482A (en)	1995-10-30
EP0609606A1 (en)	1994-08-10
CN1091005A (zh)	1994-08-24
SK65294A3 (en)	1995-03-08
CA2124677C (en)	2008-09-09
HU9401631D0 (en)	1994-08-29
JPH07504204A (ja)	1995-05-11
KR100348775B1 (ko)	2003-02-11
ATE146075T1 (de)	1996-12-15

Publication	Publication Date	Title
SI9300514A (en)	1994-06-30	Immunopotentiatory agent and physiologically acceptable salts thereof
US6197743B1 (en)	2001-03-06	Compositions and methods for the treatment of viral disorders
AU686706B2 (en)	1998-02-12	Inhibition of smooth muscle migration and proliferation with hydroxy carbazole compounds
CA2294247C (en)	2004-10-26	Antioxidant enhancement of therapy for hyperproliferative conditions
CA2263675C (en)	2010-04-13	Compositions comprising an inducing agent and an anti-viral agent for the treatment of blood, viral and cellular disorders
IE57158B1 (en)	1992-05-20	Liquid formulations of nimodipine,and a process for their preparation
JP2002523378A (ja)	2002-07-30	Ｈ２−レセプターアゴニストおよび他のｔ−細胞活性化薬剤を用いたｔ−細胞（ｃｄ４＋およびｃｄ８＋）の活性化および保護
WO2021197333A1 (zh)	2021-10-07	药物组合及其用途
AP620A (en)	1997-10-14	Uses of a flavin in the treatment of ill-effects caused by viral infections.
US5872151A (en)	1999-02-16	Immunopotentiatory agents and physiologically acceptable salts thereof
US5958980A (en)	1999-09-28	Immunopotentiatory agent and physiologically acceptable salts thereof
US6096786A (en)	2000-08-01	Immunopotentiatory agent and physiologically acceptable salts thereof
JP2002326934A (ja)	2002-11-15	ピロール誘導体を使用するための方法、キット及び組成物
JP2009501737A (ja)	2009-01-22	レイノー現象の処置のための可溶性グアニル酸シクラーゼ活性化剤の使用
CN102781444A (zh)	2012-11-14	用于治疗肝细胞癌的抗肿瘤剂或手术后辅助化学治疗剂
AU785322B2 (en)	2007-01-18	Antioxidant enhancement of therapy for hyperproliferative conditions
JPH04506517A (ja)	1992-11-12	３，３―ジ置換インドリンの鼻腔内投与
JPS58174324A (ja)	1983-10-13	線溶促進剤
HK1110230A (en)	2008-07-11	Use of an inducing agent for the treatment of blood, viral and cellular disorders
JPS63239217A (ja)	1988-10-05	抗アレルギー剤